GenomOncology’s Molecular Tumor Board solution enables clinicians to make powerful decisions through a fully integrated workflow from case creation, to alteration introspection, to alteration driven treatment and clinical trial investigation, and to Molecular Tumor Board presentations. The solution can interpret comprehensive sets of next generation sequencing (NGS) variants as well as biomarker concepts and our co-occurring match algorithm combines all molecular alterations in a case with a given disease and other clinical criteria to suggest potential clinical trials and treatment options for patients.
Our solution enables your clinicians to visually view a patient’s clinical history, dig into variant information, and discover potential treatment options quickly and systematically.
Clinicians can view information about each variant including information about the gene, alteration in context of the disease, proximity to other pathogenic variants and annotation information from a number of databases present in the KMS for that variant.
Our solution considers the combination of every variant that has been designated as “significant” to return sensitive and resistant therapies for the patient’s tumor type, sensitive therapies for other tumor types, and prognoses according to a variety of sources including My Cancer Genome.
As of today, all cancer and biomarker-driven clinical trials from clinicaltrals.gov has been curated by Vanderbilt University’s My Cancer Genome team as a combination of disease and biomarker criteria as logical Boolean statements, resulting in ~3,000 available trials in our database.
Clinicians can view information about each clinical trial including an easy way to visualize each curated trial eligibilities, highlighting of the matched eligibilities, variants and diseases, the phase, and the recruiting status to enable quick verification of whether the trial should be recommended or not.
Our solution can separate clinical trials into trials with recruiting locations at your institution and trials only available at other institutions. This allows you to easily view and recommend clinical trials only available at your institution, while maintaining the option to view other trials when appropriate.
Our solution provides clinicians the option to view trials that match due to the absence of a particular alteration or a set of alterations that were tested for, known as wild-type match. They can also view additional partially matched trials that the patient would be eligible for if a particular variant or set of variants were tested.
Our solution creates a streamlined workflow for case creation, case analysis, and case report creation in order to help your administrative staff easily prepare presentations for Molecular Tumor Boards and reports to send to clinicians.
Our solution enables the creation of multiple groups to match your institutional Tumor Board groups. These optional groups allow you to separate different Tumor Board meetings as well as different sets of users.
Administrators can create cases that are associated with a defined group and Tumor Board meeting. Cases can also be assigned to another user so that they can add additional information to cases. A patient’s oncologic history will also be automatically populated with biopsy and prior treatment information.
Our solution gives you the flexibility to associate sample (biopsies) and lab results (assays) to a patient. When a Foundation XML is uploaded to a patient’s lab result, that association its samples, assays, and panels enable the system to understand which variants were tested for and which variants were not automatically.
When preparing for a Tumor Board meeting, our meeting explorer enables users to define which cases will be presented in the meeting, preview the Tumor Board Presentation, and edit the date or time of the meeting if needed.
We created a view within our solution to make it easier for administrators to prepare for their Tumor Board meetings. This “Presentation View” enables users to set attendees, re-order cases for presentation, and select whether or not they want to include information within the presentation through simple checkboxes.
The presentation can be saved at any time by users so the information selected to be included in a presentation or report can be updated to enable you to create multiple reports for the same case or meeting. Users can export presentations as slides, meeting summaries as PDFs, and case summaries as PDFs.
Our solution is designed to be a fully integrated system that collaboratively works with your existing molecular infrastructures (Sequencing pipeline, Clinical Data Warehouse and EHR) rather than add extra steps to your process with the end result of automating case creation in the Tumor Board Application through the Knowledge Management System (KMS).